1
|
Hou W, Dai W, Huang H, Liu SL, Liu J, Huang LJ, Huang XH, Zeng JL, Gan ZW, Zhang ZY, Lan JX. Pharmacological activity and mechanism of pyrazines. Eur J Med Chem 2023; 258:115544. [PMID: 37300915 DOI: 10.1016/j.ejmech.2023.115544] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Revised: 05/25/2023] [Accepted: 06/03/2023] [Indexed: 06/12/2023]
Abstract
Heterocycles are common in the structure of drugs used clinically to deal with diseases. Such drugs usually contain nitrogen, oxygen and sulfur, which possess electron-accepting capacity and can form hydrogen bonds. These properties often bring enhanced target binding ability to these compounds when compared to alkanes. Pyrazine is a nitrogen-containing six-membered heterocyclic ring and many of its derivatives are identified as bioactive molecules. We review here the most active pyrazine compounds in terms of their structure, activity in vitro and in vivo (mainly antitumor activity) and the reported mechanisms of action. References have been downloaded through Web of Science, PubMed, Science Direct, Google Scholar and SciFinder Scholar. Publications reporting only the chemistry of pyrazine derivatives are beyond the scope of this review and have not been included. We found that compounds in which a pyrazine ring was fused into other heterocycles especially pyrrole or imidazole were the highly studied pyrazine derivatives, whose antineoplastic activity had been widely investigated. To the best of our knowledge, this is the first review of pyrazine derivatives and their bioactivity, especially their antitumor activity. This review should be useful for those engaged in development of medications based on heterocyclic compounds especially those based on pyrazine.
Collapse
Affiliation(s)
- Wen Hou
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Wei Dai
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Hao Huang
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Sheng-Lan Liu
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Jun Liu
- College of Pharmacy, Jinan University, Guangzhou, 510632, PR China
| | - Le-Jun Huang
- College of Rehabilitation, Gannan Medical University, Ganzhou, 341000, PR China
| | - Xian-Hua Huang
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Jun-Lin Zeng
- HuanKui Academy, Nanchang University, Nanchang, 330006, PR China
| | - Zhi-Wei Gan
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Zhen-Yu Zhang
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, PR China
| | - Jin-Xia Lan
- College of Public Health and Health Management, Gannan Medical University, Ganzhou, 341000, PR China.
| |
Collapse
|
2
|
Design, Fabrication and Evaluation of Stabilized Polymeric mixed micelles for Effective Management in Cancer Therapy. Pharm Res 2022; 39:2761-2780. [PMID: 36171346 DOI: 10.1007/s11095-022-03395-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 09/09/2022] [Indexed: 10/14/2022]
Abstract
PURPOSE Cancer is one of the most common and fatal disease, chemotherapy is the major treatment against many cancer types. The anti-apoptotic BCL-2 protein's expression was increased in many cancer types and Venetoclax (VLX; BCL-2 inhibitor) is a small molecule, which selectively inhibits this specified protein. In order to increase the clinical performance of this promising inhibitor as a repurposed drug, polymeric mixed micelles formulations approach was explored. METHODS The Venetoclax loaded polymeric mixed micelles (VPMM) were prepared by using Pluronic® F-127 and alpha tocopherol polyethylene glycol 1000 succinate (TPGS) as excipients by thin film hydration method and characteristics. The percentage drug loading capacity, entrapment efficiency and in-vitro drug release studies were performed using HPLC method. The cytotoxicity assay, cell uptake and anticancer activities were evaluated in two different cancer cells i.e. MCF-7 (breast cancer) and A-549 (lung cancer). RESULTS Particle size, polydispersity index and zeta potential of the VPMM was found to be 72.88 ± 0.09 nm, 0.078 ± 0.009 and -4.29 ± 0.24 mV, respectively. The entrapment efficiency and %drug loading were found to be 80.12 ± 0.23% and 2.13% ± 0.14%, respectively. The IC50 of VLX was found to be 4.78, 1.30, 0.94 µg/ml at 24, 48 and 72 h, respectively in MCF-7 cells and 1.24, 0.68, and 0.314 µg/ml at 24, 48, and 72 h, respectively in A549 cells. Whereas, IC50 of VPMM was found to be 0.42, 0.29, 0.09 µg/ml at 24, 48 and 72 h, respectively in MCF-7 cells and 0.85, 0.13, 0.008 µg/ml at 24, 48 and 72 h in A549 cells, respectively, indicating VPMM showing better anti-cancer activity compared to VLX. The VPMM showed better cytotoxicity which was further proven by other assays and explained the anti-cancer activity is shown through the generation of ROS, nuclear damage,apoptotic cell death and expression of caspase-3,7, and 9 activities in apoptotic cells. CONCLUSION The current investigation revealed that the Venetoclax loaded polymeric mixed micelles (VPMM) revealed the enhanced therapeutic efficacy against breast and lung cancer in vitro models.
Collapse
|
3
|
Li Y, Cen Y, Fang Y, Tang S, Li S, Ren Y, Zhang H, Lu W, Xu J. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition. ACS NANO 2022; 16:12786-12800. [PMID: 35920396 PMCID: PMC9413404 DOI: 10.1021/acsnano.2c04956] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are used in ovarian cancer treatment and have greatly improved the survival rates for homologous recombination repair (HRR)-deficient patients. However, their therapeutic efficacy is limited in HRR-proficient ovarian cancer. Thus, sensitizing HRR-proficient ovarian cancer cells to PARP inhibitors is important in clinical practice. Here, a nanodrug, olaparib-Ga, was designed using self-assembly of the PARP inhibitor olaparib into bovine serum albumin through gallic acid gallium(III) coordination via a convenient and green synthetic method. Compared with olaparib, olaparib-Ga featured an ultrasmall size of 7 nm and led to increased suppression of cell viability, induction of DNA damage, and enhanced cell apoptosis in the SKOV3 and OVCAR3 HRR-proficient ovarian cancer cells in vitro. Further experiments indicated that the olaparib-Ga nanodrug could suppress RRM2 expression, activate the Fe2+/ROS/MAPK pathway and HMOX1 signaling, inhibit the PI3K/AKT signaling pathway, and enhance the expression of cleaved-caspase 3 and BAX protein. This, in turn, led to increased cell apoptosis in HRR-proficient ovarian cancer cells. Moreover, olaparib-Ga effectively restrained SKOV3 and OVCAR3 tumor growth and exhibited negligible toxicity in vivo. In conclusion, we propose that olaparib-Ga can act as a promising nanodrug for the treatment of HRR-proficient ovarian cancer.
Collapse
Affiliation(s)
- Yangyang Li
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
| | - Yixuan Cen
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
| | - Yifeng Fang
- Department
of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang, China
| | - Sangsang Tang
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
| | - Sen Li
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
| | - Yan Ren
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
| | - Hongbo Zhang
- Pharmaceutical
Sciences Laboratory, Åbo Akademi University, Turku FI-20520, Finland
- Turku
Bioscience Centre, University of Turku and
Åbo Akademi University, Turku FI-20520, Finland
| | - Weiguo Lu
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
- Department
of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, ZhejiangChina
- Cancer
Center, Zhejiang University, Hangzhou 310058, Zhejiang, China
| | - Junfen Xu
- Women’s
Reproductive Health Laboratory of Zhejiang Province, Women’s
Hospital, Zhejiang University School of
Medicine, Hangzhou 310006, Zhejiang, China
- Department
of Gynecologic Oncology, Women’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, ZhejiangChina
| |
Collapse
|
4
|
Zheng Y, Li B, Ai Y, Chen M, Zheng X, Qi J. Synthesis, crystal structures and anti-cancer mechanism of Cu(II) complex derived from 2-acetylpyrazine thiosemicarbazone. J COORD CHEM 2022. [DOI: 10.1080/00958972.2022.2111660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Affiliation(s)
- Yunyun Zheng
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| | - Bin Li
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| | - Yu Ai
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| | - Mengyao Chen
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| | - Xinhua Zheng
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| | - Jinxu Qi
- Medical School of Pingdingshan University, Pingdingshan, Henan, China
| |
Collapse
|
5
|
Mostafa N, Salem A, Mansour SZ, El-Sonbaty SM, Moawed FSM, Kandil EI. Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges. Technol Cancer Res Treat 2022; 21:15330338221085376. [PMID: 35382635 PMCID: PMC8990695 DOI: 10.1177/15330338221085376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2021] [Revised: 02/07/2022] [Accepted: 02/11/2022] [Indexed: 01/10/2023] Open
Abstract
Introduction: In the fight against cancer, cisplatin is most widely used as a clinical mainstay for the chemotherapy of various human cancers. Meanwhile, its cytotoxic profile, as well as drug resistance, limits its widespread application. The goal of precision medicine is to tailor an optimized therapeutic program based on the biology of the disease. Recently, nanotechnology has been demonstrated to be promising in this scenario. Objective: The current work provides a rationale for the design of an alternative oncology trial for the treatment of hepatocarcinogenesis using a novel eco-friendly nanocomplex, namely gallic acid-coated gallium nanoparticles. Moreover, the study tests whether the antineoplastic efficacy of gallic acid-coated gallium nanoparticles could be enhanced or not when it is administrated together with cisplatin. Methods: The work comprised a series of both in vitro and in vivo investigations. The in vivo therapeutic efficacy of such treatments, against diethylnitrosamine-induced hepatocarcinogenesis, was strictly evaluated by tracking target genes expressions, iron homeostasis, diverse biomarkers alterations, and lastly, routine paraclinical investigations were also assessed. Results: The in vitro biological evaluation of gallic acid-coated gallium nanoparticles in a HepG-2 cancer cell line established its superior cytotoxicity. Else more, the results of the in vivo experiment highlighted that gallic acid-coated gallium nanoparticles could diminish key hallmarks of cancer by ameliorating most of the investigated parameters. This was well-appreciated with the histopathological findings of the liver architectures of the treated groups. Conclusions: Our findings suggest that novel biogenic Ga-based nanocomplexes may potentially present new hope for the development of alternative liver cancer therapeutics, which should attract further scientific interest.
Collapse
Affiliation(s)
- Nihal Mostafa
- Department of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt
| | - Ahmed Salem
- Department of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt
| | - Somaya Z Mansour
- Radiation Biology, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt
| | - Sawsan M El-Sonbaty
- Radiation Microbiology, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt
| | - Fatma S M Moawed
- Health Radiation Research, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt
| | - Eman I Kandil
- Department of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt
| |
Collapse
|
6
|
Fei W, Zhang Y, Ye Y, Li C, Yao Y, Zhang M, Li F, Zheng C. Bioactive metal-containing nanomaterials for ferroptotic cancer therapy. J Mater Chem B 2021; 8:10461-10473. [PMID: 33231601 DOI: 10.1039/d0tb02138e] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The clinical performance of the current cancer therapies is still far from satisfactory. The emerging ferroptosis-driven therapy strategies reignite the hope of chemotherapy in tumor treatment due to their incredible tumor suppression. Among ferroptosis-based cancer therapies, metal elements have attracted remarkable attention due to their inherent physicochemical properties in inducing ferroptosis of tumor cells quickly and strongly without complex cellular signal transduction. Although the discovery and applications of ferroptosis for tumor treatment have been discussed in many reviews, the unique advantages of metal-containing nanomaterials interfering ferroptotic cancer therapies (MIFCT) have seldom been mentioned. Here, we outline the latest advances of MIFCT comprehensively. Firstly, the functions of different kinds of metal elements or their ions are introduced to illustrate their advantages in MIFCT. Secondly, the emerging metal-containing nanomaterials that are designed to achieve ferroptosis-driven therapy are overviewed, including their ability to boost the Fenton or Fenton-like reaction for reactive oxygen species generation, act as hydrogen peroxide self-providers, damage the reducing system, and disturb cellular communication. Moreover, metal-containing nanomaterials with external energy conversion features for MIFCT are discussed. Finally, the future expectations and challenges of MIFCT for clinical cancer therapy are spotlighted.
Collapse
Affiliation(s)
- Weidong Fei
- Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
| | - Yue Zhang
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
| | - Yiqing Ye
- Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
| | - Chaoqun Li
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
| | - Yao Yao
- Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
| | - Meng Zhang
- Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
| | - Fanzhu Li
- College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
| | - Caihong Zheng
- Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
| |
Collapse
|
7
|
Qi J, Zhao W, Zheng Y, Wang R, Chen Q, Wang FA, Fan W, Gao H, Xia X. Single-crystal structure and intracellular localization of Zn(II)-thiosemicarbazone complex targeting mitochondrial apoptosis pathways. Bioorg Med Chem Lett 2020; 30:127340. [PMID: 32631541 DOI: 10.1016/j.bmcl.2020.127340] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2020] [Revised: 05/17/2020] [Accepted: 06/06/2020] [Indexed: 01/01/2023]
Abstract
Tracking of drugs in cancer cells is important for basic biology research and therapeutic applications. Therefore, we designed and synthesised a Zn(II)-thiosemicarbazone complex with photoluminescent property for organelle-specific imaging and anti-cancer proliferation. The Zn(AP44eT)(NO3)2 coordination ratio of metal to ligand was 1:1, which was remarkably superior to 2-((3-aminopyridin-2-yl) methylene)-N, N-diethylhydrazinecarbothioamide (AP44eT·HCl) in many aspects, such as fluorescence and anti-tumour activity. Confocal fluorescence imaging showed that the Zn(AP44eT)(NO3)2 was aggregated in mitochondria. Moreover, Zn(AP44eT)(NO3)2 was more effective than the metal-free AP44eT·HCl in shortening the G2 phase in the MCF-7 cell cycle and promoting apoptosis of cancer cells. Supposedly, the effects of these complexes might be located mainly in the mitochondria and activated caspase-3 and 9 proteins.
Collapse
Affiliation(s)
- Jinxu Qi
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China.
| | - Wei Zhao
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Yunyun Zheng
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Ruiya Wang
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Qiu Chen
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Fu-An Wang
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Weiwei Fan
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Huashan Gao
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China
| | - Xichao Xia
- Medcine College of Pingdingshan University, Pingdingshan, Henan 467000, China.
| |
Collapse
|
8
|
Qi J, Liu T, Zhao W, Zheng X, Wang Y. Synthesis, crystal structure and antiproliferative mechanisms of gallium(iii) complexes with benzoylpyridine thiosemicarbazones. RSC Adv 2020; 10:18553-18559. [PMID: 35518317 PMCID: PMC9053741 DOI: 10.1039/d0ra02913k] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Accepted: 05/01/2020] [Indexed: 12/13/2022] Open
Abstract
We have prepared six thiosemicarbazone ligands and synthesized the corresponding Ga(iii) complexes. The antitumor activity of the ligand increases with its lipophilicity, and the antitumor activity of the Ga(iii) complexes is affected by the ligands. Since C6 has the highest anticancer proliferative activity (0.14 ± 0.01 μM) against HepG-2 (Human hepatocarcinoma cell line), we characterized its structure by X-ray single crystal diffraction and explored its antiproliferation mechanism. Anti-tumor mechanism results show that Ga(iii) complex (C6) promoted HepG-2 cell cycle arrest in the G1 phase by regulating the expression of cell cycle-associated proteins (Cdk 2, cyclin A and cyclin E). Ga(iii) complex (C6) promotes apoptosis by consuming intracellular iron, enhancing intracellular reactive oxygen species (ROS), activating caspase-3/9, releasing cytochromes and apoptotic protease activating factor-1 (apaf-1).
Collapse
Affiliation(s)
- Jinxu Qi
- School of Chemistry and Chemical Engineering, Southeast University Nanjing 211189 China.,School of Medicine, Pingdingshan University Pingdingshan China
| | - Taichen Liu
- School of Medicine, Pingdingshan University Pingdingshan China
| | - Wei Zhao
- School of Medicine, Pingdingshan University Pingdingshan China
| | - Xinhua Zheng
- School of Medicine, Pingdingshan University Pingdingshan China
| | - Yihong Wang
- School of Chemistry and Chemical Engineering, Southeast University Nanjing 211189 China
| |
Collapse
|
9
|
Liu N, Lin L, Wang JQ, Zhang FK, Wang JP. Tetramethylpyrazine supplementation reduced Salmonella Typhimurium load and inflammatory response in broilers. Poult Sci 2019; 98:3158-3164. [PMID: 30895324 DOI: 10.3382/ps/pez128] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2018] [Accepted: 03/13/2019] [Indexed: 12/29/2022] Open
Abstract
The present study tested whether tetramethylpyrazine (TMP) supplementation could influence the growth performance, Salmonella Typhimurium (S. Typhimurium) load, inflammasomes, cytokines, and chemokines in broilers. Treatments were a 2 × 2 factorial design, including negative control (NC), S. Typhimurium challenge (SC), and NC/SC + TMP (150 mg/kg of diet). The trial lasted for 28 D, and S. Typhimurium subclinical challenge was occurred on day 8. The results showed that S. Typhimurium challenge worsened (P < 0.05) growth performance, S. Typhimurium load in intestinal digesta and visceral tissues, intestinal inflammatory responses, and permeability compared to the NC treatment. TMP supplementation increased (P < 0.05) feed intake, weight gain, and feed efficiency by 4.3 to 12.0%, but decreased (P < 0.05) S. Typhimurium load by 5.4 to 45.8%, inflammasomes (caspase-1/3/9, gasdermin A/E, and nod-like receptor protein 3) by 25.0 to 59.0%, chemokines (C-C motif ligand 2 and C-X-C motif 10) by 40.2 to 47.2%, intestinal permeability by 28.2% compared to the SC treatment. The TMP also reduced inflammatory response by influencing tumor necrosis factor α, interleukin 1β/4/6. Factorial analysis indicated that TMP and SC were interactive (P < 0.05) on most parameters due to the more pronounced TMP effect in S. Typhimurium challenge groups. It is concluded that TMP can promote growth and mitigate S. Typhimurium infection by reducing the S. Typhimurium load and inflammatory response in broilers.
Collapse
Affiliation(s)
- N Liu
- Department of Animal Production, Henan University of Science and Technology, Luoyang 471003, China
| | - L Lin
- Department of Animal Production, Henan University of Science and Technology, Luoyang 471003, China
| | - J Q Wang
- Department of Poultry Science, University of Georgia, Athens, GA 30602
| | - F K Zhang
- Luoyang Xintai Agro-pastoral Technology Co., Ltd, Luoyang 471400, China
| | - J P Wang
- Department of Animal Production, Henan University of Science and Technology, Luoyang 471003, China
| |
Collapse
|
10
|
Synthesis, anticancer activity and mechanism of iron chelator derived from 2,6-diacetylpyridine bis(acylhydrazones). J Inorg Biochem 2019; 193:1-8. [DOI: 10.1016/j.jinorgbio.2019.01.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 01/01/2019] [Accepted: 01/07/2019] [Indexed: 12/11/2022]
|
11
|
Cao W, Qi J, Qian K, Tian L, Cheng Z, Wang Y. Structure−activity relationships of 2‑quinolinecarboxaldehyde thiosemicarbazone gallium(III) complexes with potent and selective anticancer activity. J Inorg Biochem 2019; 191:174-182. [DOI: 10.1016/j.jinorgbio.2018.11.017] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 11/23/2018] [Accepted: 11/25/2018] [Indexed: 12/22/2022]
|